Is Curaleaf (TSX:CURA) still a buy?

Nick Waddell · Founder of Cantech Letter
August 11, 2026 at 10:26am ADT 2 min read
Last updated on August 11, 2026 at 10:26am ADT

Haywood Securities says Curaleaf Holdings (Curaleaf Holdings Stock Quote, Chart, News, Analysts, Financials TSX:CURA) remains well positioned despite near-term pressure in cannabis equity markets.

In an Aug. 6 update,  analyst Neal Gilmer reiterated his “Buy” rating and $17.25 target on Curaleaf. His target is based on 14 times his 2027 EBITDA estimate, discounted at 15%.

“Curaleaf reported Q2 results that were ahead of expectations,” Gilmer said. “Growth was once again driven by international markets, increasing 26% while the domestic segment grew by 7%.”

Curaleaf reported Q2 revenue of $340.1-million, up 9.5% year-over-year and above Gilmer’s $332.3-million forecast. Adjusted EBITDA was $70.1-million, representing a 20.6% margin and ahead of his $67.2-million estimate.

Adjusted gross margin improved sequentially to 50.2%, above Gilmer’s 48.5% forecast. Cash from operations was $29-million, while free cash flow was $13-million after $16-million of capital spending.

The company ended the quarter with $107.0-million of cash and $611.5-million of debt, net of unamortized discounts.

During the quarter, Curaleaf opened two retail locations in Florida and added two more after quarter-end, bringing its Florida total to 75 and its managed retail footprint to 176 locations. The company also completed the buyout of the remaining 45% interest in Four20 Pharma.

After quarter-end, Curaleaf’s Spanish subsidiary became the first company to receive approval for two cannabis medicines.

Management guided for low-single-digit sequential revenue growth in Q3, citing improved pricing in core markets while noting consumer risks from higher energy prices and potential rate increases. It also reiterated expected 2026 capital spending of about $80-million.

Gilmer said Curaleaf has growth opportunities in international markets and adult-use sales in Maryland, Connecticut and Ohio, with further optionality in states such as Pennsylvania if adult-use cannabis is launched.

The analyst raised his EBITDA forecast after the quarter, citing cost initiatives expected to support margin expansion in the second half of the year.

Gilmer expects Curaleaf to generate Adjusted EBITDA of $287.1-million on revenue of $1.37-billion in fiscal 2026, improving to Adjusted EBITDA of $332.3-million on revenue of $1.47-billion in fiscal 2027.

 

-30-

Author photo

Nick Waddell

Founder of Cantech Letter

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

displaying rededs